Table 2b.
Variation in Utilities based on SF-6D at Baseline Survey
| Demographic | Patients with SF-6D N (%) | SF-6D Utilities Mean (SD) | SF-6D Utilities Median (IQR) |
|---|---|---|---|
|
| |||
| All | 2344 (100%) | 0.68 (0.14) | 0.66 (0.20) |
|
| |||
| Sex | |||
| Male | 1211 (51.66%) | 0.69 (0.13) | 0.66 (0.15) |
| Female | 1154 (48.34%) | 0.68 (0.14) | 0.66 (0.20) |
| p-value* | n.s | ||
|
| |||
| Race/Ethnicity | |||
| Caucasian | 1750 (74.62%) | 0.68 (0.14) | 0.66 (0.20) |
| Latino | 104 (4.44%) | 0.69 (0.15) | 0.67 (0.20) |
| African American | 277 (11.82%) | 0.68 (0.14) | 0.66 (0.20) |
| Asian | 80 (3.41 %) | 0.69 (0.12) | 0.66 (0.19) |
| Other | 133 (5.67%) | 0.66 (0.14) | 0.66 (0.19) |
| p-value** | n.s | ||
|
| |||
| Age | |||
| <=54 | 353 (15.06%) | 0.63 (0.14) | 0.62 (0.18) |
| 55-59 | 299 (12.76%) | 0.66 (0.13) | 0.64 (0.15) |
| 60-64 | 352 (15.02%) | 0.67 (0.14) | 0.66 (0.20) |
| 65-69 | 402 (17.15%) | 0.69 (0.14) | 0.66 (0.20) |
| 70-74 | 393 (16.77%) | 0.70 (0.14) | 0.68 (0.20) |
| 75-79 | 313 (13.35%) | 0.69 (0.13) | 0.67 (0.20) |
| 80+ | 232 (9.90%) | 0.72 (0.13) | 0.72 (0.24) |
| p-value** | <0.0001 | ||
|
| |||
| Stage at Diagnosis | |||
| I | 730 (31.30%) | 0.71 (0.14) | 0.70 (0.22) |
| II | 230 (9.68%) | 0.68 (0.13) | 0.66 (0.21) |
| III | 638 (27.09%) | 0.67 (0.13) | 0.66 (0.17) |
| IV | 612 (26.21%) | 0.66 (0.13) | 0.66 (0.17) |
| Unknown/Missing | 134 (5.72%) | 0.68 (0.14) | 0.67 (0.20) |
| p-value** | <0.0001 | ||
|
| |||
| Histology | |||
| NSCLC | 1979 (84.44%) | 0.68 (0.14) | 0.66 (0.23) |
| SCLC | 258 (11.01 %) | 0.68 (0.14) | 0.66 (0.20) |
| Missing | 107 (4.56%) | 0.66 (0.15) | 0.64 (0.23) |
| p-value** | n.s | ||
|
| |||
| Treatment | |||
| Surgery | 550 (23.46%) | 0.72 (0.15) | 0.72 (0.26) |
| Chemotherapy | 350 (14.93%) | 0.68 (0.14) | 0.66 (0.20) |
| Radiotherapy | 121 (5.16%) | 0.67 (0.12) | 0.66 (0.15) |
| Surgery w/Chemotherapy | 264 (11.26%) | 0.67 (0.12) | 0.66 (0.17) |
| Surgery w/Radiotherapy | 60 (2.56%) | 0.69 (0.15) | 0.68 (0.18) |
| Chemoradiotherapy | 669 (28.54%) | 0.66 (0.13) | 0.66 (0.16) |
| Surgery w/Chemo/Rad | 206 (8.79%) | 0.65 (0.14) | 0.63 (0.22) |
| No Treatment | 124 (5.29%) | 0.70 (0.13) | 0.67 (0.17) |
| p-value** | <0.0001 | ||
|
| |||
| Comorbidity | |||
| None | 409 (17.44%) | 0.69 (0.13) | 0.67 (0.21) |
| Mild | 731 (31.19%) | 0.68 (0.13) | 0.66 (0.20) |
| Moderate | 402 (17.15%) | 0.67 (0.14) | 0.66 (0.21) |
| Severe | 364 (15.53%) | 0.67 (0.14) | 0.66 (0.21) |
| Unknown/Missing | 438 (18.69%) | 0.68 (0.14) | 0.66 (0.19) |
| p-value** | n.s | ||
*
Mann-Whitney U test
**
Kruskal-Wallis test